Sonya C. Chapman

机构：Eli Lilly (United States)

发表论文 69 篇 · 总被引 977 次 · h-index 13

代表论文

• Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial (2024 · Blood · 被引 27)
• Efficacy and safety of abemaciclib alone and with PI3K / mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial (2023 · Cancer Medicine · 被引 20)
• Effects of Lacosamide, Pregabalin, and Tapentadol on Peripheral Nerve Excitability: A Randomized, Double-blind, Placebo-controlled, Crossover, Multicenter Trial in Healthy Subjects (2025 · Anesthesiology · 被引 2)
• Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study (2025 · Frontiers in Oncology · 被引 2)
• Population Pharmacokinetic Analysis of Pirtobrutinib, a reversible BTK inhibitor, in Patients with Hematological Malignancies from the Phase 1/2 BRUIN Study (2026 · Research Square)
• Longitudinal Tumor Size and Survival Modeling for Exposure–Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer (2026 · Clinical Pharmacology & Therapeutics)